Clinical trial
Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b in CHC Patients With genotype1 High Viral Load and Low Body Weight
NCT00686777 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b in CHC Patients With genotype1 High Viral Load and Low Body Weight
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- January 31, 2008
- Completion date
- December 31, 2010
- Enrollment
- 75 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.